Blood-based Biomarkers for Alzheimer's Disease at the Primary Care Level.

The Diagnostic Validity and Clinical Impact of Blood-based Biomarkers for the Diagnosis of Alzheimer's Disease at the Primary Care Level.

The goal of this study is to determine how blood biomarker tests (ptau217 and ptau217/Aβ42) performed in primary care influence the patient trajectory in individuals with cognitive concerns.

Participants will provide a blood sample for biomarker testing and undergo clinical assessments as part of diagnostic evaluation.

Inclusion Criteria:

• Patients between 55 and 85 years old who consult their PCP due to concerns about their cognitive status.

Exclusion Criteria:

• Comorbidities that would interfere with study cooperation or interpretability of study results (for instance substance abuse or cardiac, renal or hepatic failure).
• Concomitant medications that would interfere with cognitive assessments.
• A prior diagnosis of AD and related disorders or other neurodegenerative disease.